Patient Outcomes

We believe in transparency. These results are derived from de-identified clinical data across 546 patients treated through the Isha Health ketamine therapy protocol.

88.8%

of patients with moderate-to-severe symptoms showed measurable improvement

92.6%

achieved minimal anxiety (GAD-7 < 5) during treatment

546

patients analyzed with longitudinal tracking

99.1%

retention rate — only 0.92% single-session dropout

Depression outcomes (PHQ-9)

88.79% of patients who began treatment with moderate-to-severe depressive symptoms (baseline PHQ-9 ≥ 10) demonstrated measurable symptomatic improvement during their treatment course with Isha Health.

Average PHQ-9 reduction

-4.90 points

Moderate-to-severe group (baseline ≥ 10)

All patients reduction

-3.55 points

Across all severity levels

Assessments per patient

3.5 avg

Longitudinal clinical tracking

Speed of response

One of ketamine's key advantages over traditional antidepressants is rapid onset. Our data confirms this at scale.

1.29

Average sessions to first measurable improvement

Patients typically see their first measurable PHQ-9 score reduction by their second clinical assessment — compared to the 4-6 week lead time typically required for SSRIs and SNRIs.

Anxiety outcomes (GAD-7)

While ketamine is most commonly discussed for depression, our data shows equally compelling results for anxiety.

92.64% achieved minimal anxiety

Of patients tracked on the GAD-7, 92.64% reached a score below 5 — the threshold for "minimal anxiety" — at some point during their treatment course. This suggests that ketamine therapy may address both depressive and anxiety symptoms simultaneously.

Patient retention and engagement

Effective treatment means nothing if patients don't stay engaged. Our retention data suggests a high level of patient commitment to the protocol.

Average treatment duration

128 days

~4 months of active engagement

Single-session dropout

0.92%

Only 5 of 546 patients

Average mood score

5.39 / 10

Stable baseline across ~3,000 entries

Methodology

This data is derived from a retrospective analysis of de-identified clinical records from 546 unique patients treated through the Isha Health ketamine-assisted therapy protocol.

Assessment tools:

PHQ-9 (Patient Health Questionnaire-9) — validated 9-item depression severity measure, scored 0-27
GAD-7 (Generalized Anxiety Disorder-7) — validated 7-item anxiety severity measure, scored 0-21
Self-reported mood scores (1-10 scale) — collected at regular intervals during treatment

Definitions:

Moderate-to-severe symptoms: Baseline PHQ-9 score ≥ 10
Measurable improvement: Any reduction in PHQ-9 score from baseline during the treatment course
Minimal anxiety: GAD-7 score < 5 achieved at any point during treatment
Single-session dropout: Patients with only one recorded clinical assessment

Limitations:

This is a retrospective observational analysis, not a randomized controlled trial
There is no placebo control group — some improvement may be attributable to natural symptom fluctuation, placebo response, or concurrent treatments
PHQ-9 improvement was defined as any score reduction, which includes clinically modest improvements
Patients who discontinued treatment early may have different outcomes than those who completed the full protocol

These results are consistent with published literature on ketamine for treatment-resistant depression, including the landmark Murrough et al. (2013) trial and Zarate et al. (2006) study.

What this means for patients

These numbers tell a clear story: most patients who begin ketamine therapy with Isha Health experience meaningful improvement, many within their first few sessions. But the data also shows something equally important — that sustained improvement requires sustained engagement.

Our average treatment duration of 128 days reflects patients who commit to the maintenance phase, not just the initial breakthrough. This is consistent with our clinical philosophy: remission is not a destination — it is a maintained state.

If you have been struggling with depression or anxiety that hasn't responded to traditional treatments, these results suggest that ketamine therapy may offer a path forward — particularly when combined with proper preparation, psychotherapy integration, and a commitment to ongoing maintenance.

Ready to see if ketamine therapy is right for you?

Book a 60-minute consultation with an Isha Health physician.

Check Appointment Availability

Data current as of April 2026. Based on de-identified retrospective analysis of 546 patients. Individual results may vary. Ketamine is prescribed off-label for depression and anxiety — it is not FDA-approved for these indications. Safety information.